-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

704.O3.6 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT

Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Viral, Iron Deficiency, adult, Translational Research, elderly, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, GVHD, Diseases, Immune Disorders, Therapies, Immunotherapy, Infectious Diseases, Lymphoid Malignancies, Infusion, Myeloid Malignancies, Technology and Procedures, gene editing, Study Population, Human, Transplantation
Saturday, December 10, 2022: 4:00 PM-5:30 PM
Great Hall AD (Ernest N. Morial Convention Center)
Moderators:
Damian J. Green, MD, Fred Hutchinson Cancer Research Center and Hongtao Liu, MD, PhD, University of Chicago
Disclosures:
Green: BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Cellectar Biosciences: Research Funding; GSK: Membership on an entity's Board of Directors or advisory committees; Janssen Biotech: Membership on an entity's Board of Directors or advisory committees, Research Funding; Neoleukin Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno Therapeutics: Patents & Royalties, Research Funding; SpringWorks Therapeutics: Research Funding; Legend Biotech: Membership on an entity's Board of Directors or advisory committees. Liu: Agios; Pfizer; Nkarta; CTI Biopharm; Servier: Honoraria, Other: Advisory board meeting ; NGM Biopharma: Consultancy; Miltenyi Biotec: Research Funding; SITC; Academy for Continued Healthcare Learning (ACHL): Honoraria, Other: Speaker/Lecturer.
CAR studies focused on MM and post allo-HCT T cell therapies (DLI, CTL etc.)
4:00 PM

Saad Usmani, MD1, Krina Patel, MD, MSc2, Parameswaran Hari, MD, MRCP3, Jesus Berdeja, MD4, Melissa Alsina, MD**5, Ravi Vij, MD, MBBS6, Noopur Raje, MD7, Xavier Leleu, MD, PhD8, Madhav Dhodapkar, MBBS9, Ran Reshef, MD, MSc10, Anna Truppel-Hartmann, MD11*, Debashree Basudhar, PhD12*, Ethan Thompson, PhD12*, Xirong Zheng, PhD12*, Revathi Ananthakrishnan, PhD12*, Chiara Greggio, PhD12*, Linda Favre-Kontula, PhD12*, Lars Sternas, MD, PhD12* and Jesús San-Miguel, MD, PhD13

1Levine Cancer Institute, New York, NY
2Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
3Medical College of Wisconsin, Milwaukee, WI
4Sarah Cannon Research Institute, Nashville, TN
5Moffitt Cancer Center, Tampa, FL
6Washington University in St. Louis, St. Louis, MO
7Mass General Hospital Cancer Center, Boston, MA
8CHU La Milétrie, Poitiers, France
9Emory University, Atlanta, GA
10Columbia University Irving Medical Center, New York City, NY
112seventy bio, Cambridge, MA
12Bristol Myers Squibb, Princeton, NJ
13Clinica Universitaria de Navarra, Navarra, Spain

4:15 PM

Sanjeet S Dadwal, MD1, Jo-Anne H. Young, MD2*, Michael W. Schuster, MD3, Jean A. Yared, MD4, Gary Douglas Myers, MD5*, Michelle Matzko, MD, PhD6*, Sama Adnan, PhD6*, Joshua A. Hill, MD7* and Rajat Bansal, MD8*

1Department of Infectious Disease, City of Hope National Medical Center, Duarte, CA
2Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN
3Stony Brook University Hospital Cancer Center, Stony Brook, NY
4Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD
5Children's Mercy of Kansas City, Kansas City, MS
6AlloVir, Waltham, MA
7Fred Hutchinson Cancer Research Center, Seattle, WA
8Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

4:30 PM

Maria VD Soares, PhD1*, Virginia Escamilla Gomez2*, Rita I Azevedo, PhD1*, Paulo N.G. Pereira, PhD1*, Teresa Caballero Velázquez, MD, PhD2*, Clara B. Garcia-Calderón2*, Kukatharmini Tharmaratnam3*, Inês A Cabral, MSc1*, Ana C Ribeiro, MSc1*, Laura Mendes, MSc4*, Clara Juncal, MD4*, Susana Roncon, MD5*, Ana Teresa Pais, MSc1*, Ana C Alho, MD1,6*, Alfonso Rodriguez Gil, PhD2*, Eduardo L Espada, MD1,6*, Anabela Rodrigues, MD4*, Ana Garção, MD4*, Marie-Laure Yaspo, PhD7*, Hans-Jörg Warnatz, PhD7*, Hans Lehrach, PhD7*, Nuno L. Barbosa-Morais, PhD8*, Ana Miguel Quintas, MD9*, Paulo Palmela, MD10*, Cecilia Caldas, MD10*, Rosa Ferreira, MD11*, Luis Leite, MD11*, Carlos Martins, MD6*, Fernanda Lourenço, MD6*, Raúl Moreno, MD6*, João Raposo, MD12*, Fernando Campilho, MD11*, Christopher Paul Cheyne, PhD3*, Marta Garcia-Fiñana, PhD3*, António Campos, MD11*, Frédéric Baron, MD, PhD13*, Mario Arpinati, MD, PhD14, Matthias Edinger, MD, PhD15*, Jerome Ritz, MD, PhD16, Carlos Pinho Vaz, MD11*, Jose A. Perez-Simon, MD, PhD17 and Joao F Lacerda, M.D., PhD18,19

1JLacerda Lab, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
2Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío of Sevilla, Sevilla, Spain
3Department of Health Data Science, University of Liverpool, Institute of Population Health, Liverpool, United Kingdom
4Serviço de Imuno-Hemoterapia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
5Serviço de Terapia Celular, Instituto Português de Oncologia do Porto FG, Porto, Portugal
6Serviço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
7Max Planck Institute for Molecular Genetics, Berlin, Germany
8NMorais Lab, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina Universidade de Lisboa, Lisboa, Portugal
9Serviço de Oftalmologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
10Serviço de Estomatologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
11Serviço de Transplantação de Medula Óssea, Instituto Português de Oncologia do Porto, Porto, Portugal
12Serviço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
13Division of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium
14Institute of Hematology "Seràgnoli", S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy
15University Regensburg, Dept. of Hematology and Oncology, Regensburg, Germany
16Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
17Instituto de Biomedicina de Sevilla (IBiS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain
18Serviço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
19Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

4:45 PM

Susan Bal, MD1*, M. Hakan Kocoglu, MD2, Omar Nadeem, MD3, Myo Htut, MD4, Tara Gregory, MD5*, Larry D. Anderson Jr., MD, PhD6, Luciano J. Megala Costa, MD, PhD1, Tonia J. Buchholz, MS, PhD7*, Safiyyah Ziyad, PhD7*, Meng Li, PhD7*, Yanping Chen, PhD7*, Allison J. Kaeding, MD7*, Michael R. Burgess, MD, PhD7*, Kristen Hege, MD7 and Jesus Berdeja, MD8

1University of Alabama at Birmingham, Birmingham, AL
2University of Maryland, Baltimore, MD
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4City of Hope Comprehensive Cancer Center, Duarte, CA
5Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, CO
6Cellular Therapy and Hematologic Malignancies Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
7Bristol Myers Squibb, Princeton, NJ
8Sarah Cannon Research Institute, Nashville, TN

5:00 PM

Hany Elmariah, MD, MS1, Jongphil Kim, PhD2*, Kayla M. Reid, M.S.3*, Christopher Cubitt, PhD4*, Andrew Kuykendall, MD5, Jeffrey E. Lancet, MD5, Rami S. Komrokji5, David A. Sallman, MD6, Onyee Chan, MD5, Kendra Sweet, MD5, Albert J Ribickas7*, Rawan Faramand, MD3, Asmita Mishra, MD3, Farhad Khimani, MD3*, Lia Perez, MD1*, Debra Kessler, RN, MS8*, Stephanie Dormesy, BA, MPH8*, Joseph Pidala, MD, PhD3, Claudio Anasetti, MD3, Ephraim J. Fuchs, MD, MBA9, Michael D. Jain, MD, PhD3, Frederick L. Locke, MD3, Marco L. Davila, MD, PhD3, Nelli Bejanyan, MD3 and Amy E. DeZern, MD10

1Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
2Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institutte, Tampa, FL
3Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
4Immune Monitoring Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
5Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
6Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
7H. Lee Moffitt Cancer Center and Research Institute, Tampa
8New York Blood Center, New York, NY
9Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
10Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

5:15 PM

Juan Du1*, Weijun Fu2, Jing Lu2*, Wanting Qiang2*, Haiyan He2*, Jin Liu2*, Ying Yang2*, Zhongyuan Feng2*, Lina Jin2*, Xiaoqiang Fan2*, Jia Liu3*, Qi Zhang3*, Lianjun Shen3*, Lihong Weng3* and Wei Cao3*

1Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China
2Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China
3Gracell Biotechnologies Ltd., Shanghai, China

*signifies non-member of ASH